Study Melanoma with Peptide Innovations & New Literature

Published on 11/08/2022

The potential immunogenicity of mutation-derived neo-antigens makes them strong candidates for personalized cancer therapy approaches. Melanoma is associated with a high somatic mutation frequency leading to an increased likelihood of neo-antigen formation. 
Besides the need for therapy, this cancer is also a suitable model for neo-epitope prediction and verification. Vaccine and cell therapy development [6,7] as well as the implementation of appropriate humoral and cellular immune monitoring strategies are often pioneered in melanoma research.
Therefore, we developed a large variety of readily available peptide-based tools and services supporting all development phases of Melanoma-related Immunotherapies.  

  • common melanoma- associated antigens, e.g. MAGE, PRAME or NY-ESO, with new products continuously added to the catalog
  • for T-cell immunity profiling & epitope discovery

  • immunodominant epitopes representing melanoma-associated antigens 
  • for stimulation of antigen-specific T cells in T cell assays

  • high density or multiwell peptides microarrays
  • for epitope resolved humoral immune response profiling and antibody epitope mapping

The following list of publications exemplifies the range of our products, and their applicability in recent cancer immunotherapy research:
  1. Lanscape of Helper and Regulatory Antitumour CD4+ T cells in Melanoma
    Oliveira et al., Nature (2022) – PMID: 35508657  
  2. Local Delivery of low-dose anti–CTLA-4 to the Melanoma Lymphatic Basin leads to systemic T reg Reduction and Effector T cell Activation 
    Van Pul et al., Science Immunology (2022) – PMID: 35857579 
  3. Functional T Cell Reactivity to Melanocyte Antigens is lost during the Progression of Malignant Melanoma, but Is restored by Immunization
    Przybyla et al., Cancers (Basel) (2021) – PMID: 33435427   
  4. Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell Therapies
    Stanojevic et al., Cytotherapy (2021) – PMID: 33832817  
  5. Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
    Akache et al., Pharmaceutics (2021) – PMID: 33673382
  6. Neoantigens in Cancer Immunotherapy – Review
    Schumacher & Schreiber, Science (2015) – PMID: 25838375 
  7. An immunogenic personal Neoantigen Vaccine for Patients with Melanoma – Letter
    Ott et al., Nature (2017) – PMID: 28678778  

Find more references.

If you have any questions or want to discuss our large varity of custom peptide synthesis formats, pease contact us.

Check our list of products, click and go.

Get a quote